China’s Growing Biopharma Market: How Outsourcing is Playing a Role

A recent study from Wise Guy Reports market research firm points to steady worldwide growth in biopharma outsourcing, with China marked as a leader in the field. A number of well-respected contract companies in China provide drug discovery and development services, as well as standard clinical trials. Cost-saving manufacturing, packaging and non-clinical services are also expected to grow in the country, driving a healthy Compound Annual Growth Rate (CAGR) between now and 2025.

The growth is due to technological development and the boundary-pushing possibilities of the digital era. Everything-as-a-service (XaaS) solutions are impacting the biopharma and biotech space, allowing a new, wider range of consumers to access AI technologies and Internet of Things (IoT)-based solutions. In order to adapt to this new tech frontier, professionals need biopharmaceutical courses that take these changes into account.

The impact of rapid technological development and adoption is changing the way biopharmaceutical courses are delivered and taught. At CfPIE, our goal is not to prepare you for today, but for tomorrow’s industry innovations. Our instructors are real-world experts who have worked in biopharma and know the challenges that professionals face on a daily basis. Consistent training is a must in this field, and our Biopharmaceutical Development Certified Professional program is designed to keep you on the cutting edge in biotech discovery, development and manufacture.



The study details the outsourcing market to 2025, including growth potential, opportunities and industry-specific challenges and risks. For professionals in biotech, it’s a must read to help plot the course of your career and the growth of the industry. Attention is paid to each global market and its forecasted growth, with China expecting to be a leader in both production and consumption. Head to Wise Guy Reports to read more about the industry forecast.